Xenetic Biosciences, Inc. (NASDAQ:XBIO)

BRIEF

published on 03/26/2025 at 14:05, 10 months 5 days ago

Xenetic Biosciences' Partner Enters Clinical Study to Advance DNase Platform

Xenetic Biosciences Cancer Treatment Clinical Study DNase Platform Osteosarcoma
PRESS RELEASE

published on 03/26/2025 at 14:00, 10 months 5 days ago

Xenetic Biosciences, Inc. Announces Entry by Collaboration Partner into a Clinical Study Agreement to Advance Development of DNase Platform for the Treatment of Relapsed/Refractory Osteosarcoma and Ewing Sarcoma
Xenetic Biosciences, Inc. collaborates with PeriNess Ltd. on a clinical study at Tel-Aviv Sourasky Medical Center to evaluate DNase I candidate XBIO-015 in osteosarcoma and Ewing sarcoma patients

Xenetic Biosciences Clinical Study DNase I PeriNess Ltd. Osteosarcoma
BRIEF

published on 03/19/2025 at 13:10, 10 months 12 days ago

Xenetic Biosciences Reports 2024 Financial Results

Financial Results Cancer Treatment Clinical Development Collaborations DNase Technology
PRESS RELEASE

published on 03/19/2025 at 13:05, 10 months 12 days ago

Xenetic Biosciences, Inc. Reports Full Year 2024 Financial Results
Xenetic Biosciences reports encouraging preclinical data on DNase-based technology targeting NETosis for difficult cancers. Focus on clinical studies partnerships and DNase I development program for pancreatic carcinoma

Xenetic Biosciences Preclinical Data Clinical Studies DNase-based Technology NETosis
BRIEF

published on 03/13/2025 at 13:35, 10 months 18 days ago

Xenetic Biosciences Reveals Promising Preclinical Data for DNase I in Cancer Therapy

Xenetic Biosciences Cancer Treatment Preclinical Data DNase I Therapy CAR T Cells
PRESS RELEASE

published on 03/13/2025 at 13:30, 10 months 18 days ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Underscoring the Potential of DNase I as an Adjunctive Treatment to Enhance Immunotherapeutic Responses
Xenetic Biosciences presents promising findings on combining DNase I with CAR T cells to enhance cancer treatment strategies at the SITC Spring Scientific 2025 Cell Therapy Meeting

Xenetic Biosciences Cancer Treatment DNase I CAR T Cells SITC Spring Meeting
BRIEF

published on 02/27/2025 at 15:20, 11 months 1 day ago

Xenetic Biosciences' Abstract Accepted for SITC 2025 Meeting

Xenetic Biosciences Immuno-oncology Cell Therapy DNase Platform SITC 2025
PRESS RELEASE

published on 02/27/2025 at 15:15, 11 months 1 day ago

Xenetic Biosciences, Inc. Announces Abstract Accepted for Poster Presentation at the Society for Immunotherapy of Cancer (SITC) Spring Scientific 2025 Cell Therapy Meeting
Xenetic Biosciences announces abstract acceptance for SITC Spring Scientific 2025 Cell Therapy Meeting on targeting Neutrophil Extracellular Traps in Metastatic Melanoma

Xenetic Biosciences DNase Platform Poster Presentation Immuno-oncology Technologies SITC Spring Scientific 2025
BRIEF

published on 12/17/2024 at 15:20, 1 year 1 month ago

Xenetic Biosciences Extends Research Agreement with University of Virginia

Xenetic Biosciences University Of Virginia Cancer Treatment DNase Platform Immune-oncology
PRESS RELEASE

published on 12/17/2024 at 15:15, 1 year 1 month ago

Xenetic Biosciences, Inc. Releases Virtual Investor "What This Means" Segment
Xenetic extends Research Agreement with University of Virginia for DNase-Based oncology platform. Dr. Reid Bissonnette discusses the advancement of innovative immune-oncology technologies

University Of Virginia Xenetic Research Agreement DNase-Based Oncology Platform

Published on 01/31/2026 at 03:15, 1 day 9 hours ago

Empress Royalty Announces Grant Of Restricted Share Units
Published on 01/31/2026 at 02:20, 1 day 9 hours ago

Boron One Announces First Closing of Financing
Published on 01/31/2026 at 01:40, 1 day 10 hours ago

Star Copper Announces Grant of RSUs, Stock Options and PSUs
Published on 01/31/2026 at 00:00, 1 day 12 hours ago

BE Resources Announces Private Placement
Published on 01/30/2026 at 23:00, 1 day 13 hours ago

Avidian Gold Corp. Announces Director Resignation

View all ACCESSWIRE

Published on 01/31/2026 at 15:54, 20 hours 24 minutes ago

EQS-Adhoc: Wolford AG: Capital increase will not be implemented
Published on 01/31/2026 at 12:25, 23 hours 54 minutes ago

JOHNNIE WALKER TOASTS MUSIC'S BIGGEST WEEKEND WITH THE GO GO HIGHBALL
Published on 01/31/2026 at 02:45, 1 day 9 hours ago

CANADA BACKS NEW DEFENCE, SECURITY AND RESILIENCE BANK
Published on 01/30/2026 at 22:00, 1 day 14 hours ago

Nebius Group N.V. announces date of fourth quarter and full year 2025 results and conference call
Published on 01/30/2026 at 20:10, 1 day 16 hours ago

Cynosure Lutronic Announces Completion of EU MDR Approval and Global Momentum for Mosaic 3D™ Ahead of IMCAS 2026

View all EQS

Published on 01/30/2026 at 17:45, 1 day 18 hours ago

Schneider Electric launches a capital increase reserved for employees
Published on 01/30/2026 at 08:00, 2 days 4 hours ago

AMA: 4th Quarter & FY 2025 Revenues
Published on 01/29/2026 at 18:00, 2 days 18 hours ago

GUILLEMOT CORPORATION: FULL-YEAR 2025 CONSOLIDATED TURNOVER UP 2%
Published on 01/29/2026 at 17:45, 2 days 18 hours ago

LANSON-BCC ANNOUNCES 2025 REVENUES AND FINALISES THE ACQUISITION OF HEIDSIECK & C° MONOPOLE
Published on 01/29/2026 at 17:45, 2 days 18 hours ago

Cegedim generated LFL revenue growth of 1.1% in 2025

View all LES ECHOS COMFI WIRE

News